Stockholders' Deficit	12 Months Ended
Apr. 30, 2020
Stockholders' Equity Note [Abstract]
Stockholders' Deficit	NOTE 8: STOCKHOLDERS’ DEFICIT Common Stock The Company has 300,000,000 shares of common stock authorized with a par value of $0.001 per share. As of April 30, 2020, the Company had 24,749,354 shares of common stock issued and outstanding. Equity Transactions During Year Ended April 30, 2019 On May 15, 2018, the Company cancelled 240,000 of its common shares and accrued a stock refund payable of $1,200 as of April 30, 2019. Equity Transactions During Year Ended April 30, 2020 On March 2, 2020, the Company issued 369,354 shares of common stock for the conversion of outstanding convertible notes payable of $125,000 and accrued interest of $4,274. Upon conversion of the note payable balance, the derivative liability amount of $53,571 was reclassified as additional paid-in capital as part of stockholders’ equity. The purchase price of $332,239 under the Stock Purchase Agreement (see Note 1) which resulted in shares of Lazex being acquired by the shareholder of SBL, was paid by SBL on behalf of the shareholder. The amount has been recorded as a distribution to shareholder and therefore is classified as a reduction of additional paid-in capital. In connection with the Stock Purchase Agreement (see Note 1), net liabilities of $15,289 were forgiven by the previous majority shareholder of the Company which was recorded as an increase to additional paid-in capital. On March 16, 2020, the Company issued warrants valued at $112,990 in connection with a note payable (see Note 6) which increased additional paid-in capital. Common Stock Issuable As discussed in Note 5, on September 16, 2019, the Company entered into a warrant assignment and conveyance agreement with Montsaic, pursuant to which the Company allows Montsaic to acquire 33% of the outstanding common stock shares of the Company on a fully-diluted basis for no consideration. The allocated value of the warrant amounted to $1,492,188, which has been reflected as additional paid-in capital. There are 8,137,859 shares of common stock that are issuable under this agreement. As of April 30, 2020, none of these shares have been issued. Warrants Issued for Compensation On April 30, 2020, the Company granted an aggregate total of 12,500,000 warrants to key employees and officers of the Company as compensation. The warrants have an exercise price of $0.001 per share, a contractual life of 10 years from the date of issuance, and are vested immediately upon grant. The warrants granted as compensation during the year ended April 30, 2020 were valued using the Black-Scholes pricing method. The total stock-based compensation expense related to the issuance of the warrants amounted to $3,741,746.

Stockholders' Deficit

12 Months Ended

Apr. 30, 2020

Stockholders' Equity Note [Abstract]

NOTE 8: STOCKHOLDERS’ DEFICIT

Common Stock

The Company has 300,000,000 shares of common stock authorized with a par value of $0.001 per share. As of April 30, 2020, the Company had 24,749,354 shares of common stock issued and outstanding.

Equity Transactions During Year Ended April 30, 2019

On May 15, 2018, the Company cancelled 240,000 of its common shares and accrued a stock refund payable of $1,200 as of April 30, 2019.

Equity Transactions During Year Ended April 30, 2020

On March 2, 2020, the Company issued 369,354 shares of common stock for the conversion of outstanding convertible notes payable of $125,000 and accrued interest of $4,274. Upon conversion of the note payable balance, the derivative liability amount of $53,571 was reclassified as additional paid-in capital as part of stockholders’ equity.

The purchase price of $332,239 under the Stock Purchase Agreement (see Note 1) which resulted in shares of Lazex being acquired by the shareholder of SBL, was paid by SBL on behalf of the shareholder. The amount has been recorded as a distribution to shareholder and therefore is classified as a reduction of additional paid-in capital.

In connection with the Stock Purchase Agreement (see Note 1), net liabilities of $15,289 were forgiven by the previous majority shareholder of the Company which was recorded as an increase to additional paid-in capital.

On March 16, 2020, the Company issued warrants valued at $112,990 in connection with a note payable (see Note 6) which increased additional paid-in capital.

Common Stock Issuable

As discussed in Note 5, on September 16, 2019, the Company entered into a warrant assignment and conveyance agreement with Montsaic, pursuant to which the Company allows Montsaic to acquire 33% of the outstanding common stock shares of the Company on a fully-diluted basis for no consideration. The allocated value of the warrant amounted to $1,492,188, which has been reflected as additional paid-in capital.

There are 8,137,859 shares of common stock that are issuable under this agreement. As of April 30, 2020, none of these shares have been issued.

Warrants Issued for Compensation

On April 30, 2020, the Company granted an aggregate total of 12,500,000 warrants to key employees and officers of the Company as compensation. The warrants have an exercise price of $0.001 per share, a contractual life of 10 years from the date of issuance, and are vested immediately upon grant. The warrants granted as compensation during the year ended April 30, 2020 were valued using the Black-Scholes pricing method. The total stock-based compensation expense related to the issuance of the warrants amounted to $3,741,746.